PMID- 20859537
OWN - NLM
STAT- MEDLINE
DCOM- 20101203
LR  - 20211020
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 6
DP  - 2010 Sep 7
TI  - Levosimendan neither improves nor worsens mortality in patients with cardiogenic 
      shock due to ST-elevation myocardial infarction.
PG  - 657-63
AB  - BACKGROUND: The aim of this study was to evaluate the effect of levosimendan on 
      mortality in cardiogenic shock (CS) after ST elevation myocardial infarction 
      (STEMI). METHODS AND RESULTS: Data were obtained prospectively from the SCAAR 
      (Swedish Coronary Angiography and Angioplasty Register) and the RIKS-HIA 
      (Register of Information and Knowledge about Swedish Heart Intensive Care 
      Admissions) about 94 consecutive patients with CS due to STEMI. Patients were 
      classified into levosimendan-mandatory and levosimendan-contraindicated cohorts. 
      Inotropic support with levosimendan was mandatory in all patients between January 
      2004 and December 2005 (n = 46). After the SURVIVE and REVIVE II studies were 
      presented, levosimendan was considered contraindicated and was not used in 
      consecutive patients between December 2005 and December 2006 (n = 48). The 
      cohorts were similar with respect to pre-treatment characteristics and 
      concomitant medications. There was no difference in the incidence of new-onset 
      atrial fibrillation, in-hospital cardiac arrest and length of stay at the 
      coronary care unit. There was no difference in adjusted mortality at 30 days and 
      at one year. CONCLUSION: The use of levosimendan neither improves nor worsens 
      mortality in patients with CS due to STEMI. Well-designed randomized clinical 
      trials are needed to define the role of inotropic therapy in the treatment of CS.
FAU - Omerovic, Elmir
AU  - Omerovic E
AD  - Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. 
      elmir@wlab.gu.se
FAU - Ramunddal, Truls
AU  - Ramunddal T
FAU - Albertsson, Per
AU  - Albertsson P
FAU - Holmberg, Mikael
AU  - Holmberg M
FAU - Hallgren, Per
AU  - Hallgren P
FAU - Boren, Jan
AU  - Boren J
FAU - Grip, Lars
AU  - Grip L
FAU - Matejka, Goran
AU  - Matejka G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100907
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Pyridazines)
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Atrial Fibrillation/etiology
MH  - Cardiotonic Agents/*therapeutic use
MH  - Chi-Square Distribution
MH  - Cohort Studies
MH  - Electrocardiography
MH  - Female
MH  - Heart Arrest/etiology
MH  - Humans
MH  - Hydrazones/*therapeutic use
MH  - Length of Stay
MH  - Male
MH  - Myocardial Infarction/complications/*drug therapy/mortality
MH  - Myocardial Revascularization
MH  - Proportional Hazards Models
MH  - Pyridazines/*therapeutic use
MH  - Sex Factors
MH  - Shock, Cardiogenic/*drug therapy/etiology/mortality
MH  - Simendan
MH  - Statistics, Nonparametric
PMC - PMC2941779
OTO - NOTNLM
OT  - heart failure
OT  - inotropic agents
OT  - myocardial infarction
OT  - pharmacology
OT  - shock
EDAT- 2010/09/23 06:00
MHDA- 2010/12/14 06:00
PMCR- 2010/09/07
CRDT- 2010/09/23 06:00
PHST- 2010/08/25 00:00 [received]
PHST- 2010/09/23 06:00 [entrez]
PHST- 2010/09/23 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PHST- 2010/09/07 00:00 [pmc-release]
AID - vhrm-6-657 [pii]
AID - 10.2147/vhrm.s8856 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2010 Sep 7;6:657-63. doi: 10.2147/vhrm.s8856.